9 results found.

Ovarian Carcinosarcoma, Recurrent Ovarian Epithelial Cancer, Recu Clinical Trial using paclitaxel; carboplatin; ifosfamide

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary.
paclitaxel; carboplatin; ifosfamide

Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Can Clinical Trial using ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; sirolimus; laboratory biomarker analysis; sargramostim

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; sirolimus; laboratory biomarker analysis; sargramostim

Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystaden Clinical Trial using paclitaxel; docetaxel; carboplatin; bevacizumab; gemcitabine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912).
paclitaxel; docetaxel; carboplatin; bevacizumab; gemcitabine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Clinical Trial using veliparib; topotecan hydrochloride; pharmacogenomic studies; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Trial of ABT-888, an Inhibitor of Poly (ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy.
veliparib; topotecan hydrochloride; pharmacogenomic studies; pharmacological study; laboratory biomarker analysis

Male Breast Cancer, Recurrent Breast Cancer, Recurrent Fallopian Clinical Trial using mifepristone; carboplatin; gemcitabine hydrochloride; laboratory biomarker analysis; pharmacological study

University of Chicago - Recruiting 18 years or older.
- Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer.
mifepristone; carboplatin; gemcitabine hydrochloride; laboratory biomarker analysis; pharmacological study

Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Can Clinical Trial using cabozantinib-s-malate; paclitaxel; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
cabozantinib-s-malate; paclitaxel; laboratory biomarker analysis

Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Can Clinical Trial using wild-type reovirus; paclitaxel

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A RANDOMIZED PHASE II EVALUATION OF WEEKLY PACLITAXEL (NSC# 673089) VERSUS WEEKLY PACLITAXEL WITH ONCOLYTIC REOVIRUS (REOLYSIN NSC # 729968, BB-IND #13370) IN THE TREATMENT OF RECURRENT OR PERSISTENT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
wild-type reovirus; paclitaxel

Fallopian Tube Cancer, Ovarian Cancer, or Primary Peritoneal Cavi Clinical Trial using EGEN-001; pegylated liposomal doxorubicin hydrochloride; RNA analysis; laboratory biomarker analysis

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered in Combination With Pegylated Liposomal Doxorubicin (PLD, Doxil (NSC #712227 or Lipodox) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
EGEN-001; pegylated liposomal doxorubicin hydrochloride; RNA analysis; laboratory biomarker analysis

Fallopian Tube Cancer, Ovarian Cancer, or Primary Peritoneal Cavi Clinical Trial using carboplatin; ifosfamide; hyperthermia treatment

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY.
carboplatin; ifosfamide; hyperthermia treatment